AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
extrememinimalist - Author Avatar

extrememinimalist

extrememinimalist
extrememinimalist 1h ago
$TLT No one wants to do arthroscopic tomorrow otherwise it would be downTLT--
extrememinimalist
extrememinimalist 5h ago
$QQQ $SPY $NVDA Have a blue wave, folks don't care about AI. Sell $SOXL before 10 and under.NVDA--
SPY--
SOXL--
QQQ--
pit_the_prepper
pit_the_prepper 4h ago

Feels like another AI pop, then fade.

JasknTR1
JasknTR1 4h ago

Anyone else feel weirdly euphoric after this rally? Or is it just the usual post-earnings AI mania?

josemartinlopez
josemartinlopez 4h ago

From a sector lens, this looks like semis and cloud still leading, while broader tech lags. If $NVDA cools, expect SPY to underperform QQQ as growth gets squeezed. Watching AMD and MSFT for balance.

extrememinimalist
extrememinimalist 5h ago
$QQQ's big move today (Nov 18): 5,200 calls expiring Dec 18 for about $11.4M, with $309.0M in premium on roughly 523,000 contracts split evenly (neutral). Price is $656, down 0.1% today. Figures don't include 0DTE contracts. Price is below its 50-day at $714 and 200-day at $683. Source: GTA Terminal from Global Traders Academy.QQQ--
applesandpearss
applesandpearss 4h ago

Market feels like a casino today. $QQQ barely budged, yet 523k contracts traded, mostly neutral, and suddenly everyone's calling it a 'big move.' Feels like noise chasing headlines, not conviction.

BuySellHoldFinance
BuySellHoldFinance 4h ago

Not buying the 'big move' hype. Below 50/200-day, thin 0DTE, and that premium looks like thin air. I'm staying underweight QQQ until momentum flips.

Fauster
Fauster 4h ago

Seen this before; options crushes fade fast.

extrememinimalist
extrememinimalist Yesterday
$SMCI 2 million AH volume is impressiveSMCI--
SweatyDemand420
SweatyDemand420 Yesterday

Anyone have the time/price for that 2M volume? Is it premarket, and what's the average order size?

dopollak
dopollak Yesterday

Watching SMCI break out on the AH, then fading the first bid. If it holds above the open and keeps volume, I'll scalp the bounce; otherwise, likely a quick fade into the close.

Doctaglobe
Doctaglobe Yesterday

Impressive numbers, sure, but the market keeps rewarding hype over fundamentals. If SMCI can't show consistent revenue growth and clear differentiation, this kind of volume usually fades fast.

extrememinimalist
extrememinimalist Yesterday
🚨 $SLS — WHAT INCREDIBLE TIMING! 🚨 Same day SELLAS shares positive Phase 3 REGAL results, Merck says it's ending its BELLWAVE blood cancer program, including three Phase 3 trials! 🔥 Merck loses a major late-stage hematology asset. 🔥 GPS cuts death risk by 41%. 🔥 Median survival: 24 vs. 14.7 months. 🔥 SLS009 adds another potential blockbuster. 🔥 Merck stays focused on hematology. Could SELLAS be exactly what Merck needs to boost its blood cancer pipeline? While the leukemia parts differ and no acquisition talks are confirmed, the strategic possibilities are exciting! Big Pharma needs new drugs, and SELLAS just delivered strong Phase 3 survival data. Could the next big move be a partnership or buyout? The timing certainly fuels the speculation! 🚀💰 $SLS $MRK #BuyoutPotentialMRK--
SLS--
ISayBullish
ISayBullish Yesterday

I’m not chasing SELLAS until we see a credible partner timeline. If MRK signals interest, I’ll nibble. Otherwise, I’ll wait for a pullback and buy dips, hedged with puts. Volatility’s fine if it creates value.

BoomsRoom
BoomsRoom Yesterday

Seen this movie with Takeda and AstraZeneca buying smaller players after late-stage wins. But pharma deals take years to close, and regulatory hurdles can derail everything. If Merck does engage, it’ll likely be a staged partnership, not a quick buyout.

donutloop
donutloop Yesterday

Why do we always chase headlines before any deal?

extrememinimalist
extrememinimalist Yesterday
$AMZN this is really disappointingAMZN--
hillramo
hillramo Yesterday

Everyone’s leaning bearish on AMZN after the miss, but I’m seeing a classic capitulation setup: guidance cuts, weak print, yet the stock still trades with some cushion. If sentiment cools further, risk/reward flips.

FlowLongjumping8948
FlowLongjumping8948 Yesterday

Seen this movie with Amazon before—revenue growth slows, costs creep up, guidance gets trimmed, and the market whipsaws for weeks. The real test is execution on Prime and AWS. Patience usually pays, but patience has a price.

Djtrickyyy
Djtrickyyy Yesterday

Feels like Amazon keeps missing the mark on guidance while margins barely budged. Market patience is wearing thin.

extrememinimalist
extrememinimalist 11/16
$CELH after reaching that I'll do the 0DTE on spy when Celsius is up and live that theory. The backtest got you millionsCELH--
DORARARARARA-1
DORARARARARA-1 11/16

I’m not buying the “millions” hype. 0DTE options are brutal with slippage, bid-ask, and volatility. If CELH’s just a proxy, spreads get ugly. Feels like a fat-tail trap.

Opening-Finger-4294
Opening-Finger-4294 11/16

Interesting backtest, but 0DTE SPY strategies hinge on volatility and liquidity. If CELH reverts, does the edge hold across sessions?

ZaltWasTaken
ZaltWasTaken 11/16

Everyone’s cheering a million-dollar backtest, but 0DTE strategies are brutal in thin sessions. I doubt real-world results look this clean.

extrememinimalist
extrememinimalist 11/16
$AAL Super buy stock ticker PAIN Vector Science and Therapeutics!!!!AAL--
mints_junior
mints_junior 11/16

Feels like a classic buy-the-dip setup, but I’m uneasy. PAIN is preclinical, AAL’s leverage is real, and the market’s pricing in a miracle. If Phase 1 fails, this could sting.

vdeventa
vdeventa 11/16

Rates still high; airline debt makes this risky.

Nyghl
Nyghl 11/16

Everyone’s cheering the AAL-PAIN tie-up, but I’m oddly bullish on the underdog. If PAIN’s pipeline actually matures, AAL gets a de-risked asset. Market’s pricing this as a PR stunt; I think it’s a real catalyst.

extrememinimalist
extrememinimalist 11/16
$AMZN will hold steady around these levels until next quarter hits $300AMZN--
GoodguyGastly
GoodguyGastly 11/16

Is this a buy-the-dip setup, or wait for $300?

Colonel_Jacobs_
Colonel_Jacobs_ 11/16

Given AMZN’s guidance and the $300 target, how are you sizing the tech/retail sleeve versus cash? Are you trimming growth names and rotating into cash-flowier sectors, or keeping exposure steady until the next catalyst?

THKY
THKY 11/16

Trend looks sideways: higher lows, lower highs, volume hasn’t spiked. Until we see a clean push above $300 with conviction, momentum traders probably stay on the sidelines. Watching relative strength versus MSFT and GOOGL.

Scroll to load more